Is ATNM or PMN more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Promis Neurosciences N/A -143.09% -109.15%

Is ATNM or INO more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Inovio Pharmaceuticals N/A -669.94% -73.97%

Is BDTX or ATNM more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Actinium Pharmaceuticals N/A -100.85% -47.89%

Actinium Pharmaceuticals (ATNM) Competitors

$1.01 +0.01 (+1.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

ATNM vs. PMN, CBUS, INO, BDTX, and ADCT

Should you buy Actinium Pharmaceuticals stock or one of its competitors? Actinium Pharmaceuticals's main competitors and comparable companies include Promis Neurosciences (PMN), Cibus (CBUS), Inovio Pharmaceuticals (INO), Black Diamond Therapeutics (BDTX), and ADC Therapeutics (ADCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Actinium Pharmaceuticals compare to Promis Neurosciences?

Actinium Pharmaceuticals (NYSE:ATNM) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Actinium Pharmaceuticals' return on equity of -100.85% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Promis Neurosciences	N/A	-143.09%	-109.15%

Promis Neurosciences has lower revenue, but higher earnings than Actinium Pharmaceuticals. Promis Neurosciences is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.90	-$48.82M	$0.36	2.81
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

Actinium Pharmaceuticals has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market.

In the previous week, Promis Neurosciences had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 1 mentions for Promis Neurosciences and 0 mentions for Actinium Pharmaceuticals. Promis Neurosciences' average media sentiment score of 1.87 beat Actinium Pharmaceuticals' score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Promis Neurosciences	Very Positive

Actinium Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 395.05%. Promis Neurosciences has a consensus price target of $34.00, indicating a potential upside of 146.73%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Actinium Pharmaceuticals beats Promis Neurosciences on 8 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Cibus?

Cibus (NASDAQ:CBUS) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

In the previous week, Cibus had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 1 mentions for Cibus and 0 mentions for Actinium Pharmaceuticals. Cibus' average media sentiment score of 1.87 beat Actinium Pharmaceuticals' score of 0.00 indicating that Cibus is being referred to more favorably in the media.

Company	Overall Sentiment
Cibus	Very Positive
Actinium Pharmaceuticals	Neutral

Actinium Pharmaceuticals has higher revenue and earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$4.35M	29.01	-$127.08M	-$1.65	N/A
Actinium Pharmaceuticals	$35.09M	0.90	-$48.82M	$0.36	2.81

33.8% of Cibus shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 29.9% of Cibus shares are held by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cibus presently has a consensus price target of $9.00, indicating a potential upside of 445.45%. Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 395.05%. Given Cibus' higher possible upside, equities research analysts clearly believe Cibus is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Actinium Pharmaceuticals has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Actinium Pharmaceuticals' return on equity of -100.85% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Cibus has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Summary

Cibus beats Actinium Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Inovio Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Inovio Pharmaceuticals had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Inovio Pharmaceuticals and 0 mentions for Actinium Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.21 beat Actinium Pharmaceuticals' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Inovio Pharmaceuticals	Positive

Actinium Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 395.05%. Inovio Pharmaceuticals has a consensus price target of $3.17, suggesting a potential upside of 145.48%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Actinium Pharmaceuticals has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Actinium Pharmaceuticals' return on equity of -100.85% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Actinium Pharmaceuticals has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.90	-$48.82M	$0.36	2.81
Inovio Pharmaceuticals	$60K	2,223.10	-$84.95M	-$0.91	N/A

Summary

Actinium Pharmaceuticals beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Black Diamond Therapeutics has a beta of 3.28, meaning that its stock price is 228% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 0 mentions for Actinium Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 1.80 beat Actinium Pharmaceuticals' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Very Positive
Actinium Pharmaceuticals	Neutral

Black Diamond Therapeutics' return on equity of -32.10% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Black Diamond Therapeutics has higher earnings, but lower revenue than Actinium Pharmaceuticals. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A
Actinium Pharmaceuticals	$35.09M	0.90	-$48.82M	$0.36	2.81

Black Diamond Therapeutics currently has a consensus price target of $9.80, indicating a potential upside of 339.46%. Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 395.05%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Black Diamond Therapeutics beats Actinium Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to ADC Therapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Actinium Pharmaceuticals has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.90	-$48.82M	$0.36	2.81
ADC Therapeutics	$79.58M	1.84	-$142.62M	-$0.66	N/A

Actinium Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 395.05%. ADC Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 336.68%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Actinium Pharmaceuticals is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled ADC Therapeutics'average media sentiment score.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
ADC Therapeutics	Neutral

Actinium Pharmaceuticals has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

Actinium Pharmaceuticals has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
ADC Therapeutics	-121.77%	N/A	-32.74%

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

ADC Therapeutics beats Actinium Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Actinium Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATNM vs. The Competition

Export

Metric	Actinium Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$31.76M	$3.93B	$7.20B	$24.17B
Dividend Yield	N/A	3.61%	2.54%	3.71%
P/E Ratio	-0.73	11.62	273.16	29.99
Price / Sales	0.90	1,291.80	604.48	15.29
Price / Cash	N/A	106.39	76.74	32.24
Price / Book	0.77	16.53	12.98	7.67
Net Income	-$48.82M	-$22.80M	$3.48B	$1.07B
7 Day Performance	-8.18%	-0.31%	0.13%	-0.32%
1 Month Performance	20.67%	9.80%	7.08%	1.84%
1 Year Performance	-43.26%	55.66%	24.67%	13.37%

Actinium Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATNM Actinium Pharmaceuticals	1.8692 of 5 stars	$1.01 +1.0%	$5.00 +395.0%	-43.3%	$31.76M	$35.09M	N/A	30
PMN Promis Neurosciences	3.1622 of 5 stars	$15.36 +3.8%	$34.00 +121.4%	+2.1%	$132.72M	N/A	N/A	5
CBUS Cibus	2.2126 of 5 stars	$1.68 -2.9%	$9.00 +435.7%	+23.1%	$132.22M	$3.64M	N/A	48
INO Inovio Pharmaceuticals	3.0844 of 5 stars	$1.29 +3.2%	$3.17 +145.5%	-45.6%	$129.25M	$60K	N/A	320	Positive News
BDTX Black Diamond Therapeutics	2.5841 of 5 stars	$2.24 +4.2%	$9.80 +337.5%	-18.9%	$123.81M	$70M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ATNM) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. PMN, CBUS, INO, BDTX, and ADCT

How does Actinium Pharmaceuticals compare to Promis Neurosciences?

Summary

How does Actinium Pharmaceuticals compare to Cibus?

Summary

How does Actinium Pharmaceuticals compare to Inovio Pharmaceuticals?

Summary

How does Actinium Pharmaceuticals compare to Black Diamond Therapeutics?

Summary

How does Actinium Pharmaceuticals compare to ADC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. PMN, CBUS, INO, BDTX, and ADCT

How does Actinium Pharmaceuticals compare to Promis Neurosciences?

Do institutionals and insiders have more ownership in ATNM or PMN?

Is ATNM or PMN more profitable?

Which has stronger earnings and valuation, ATNM or PMN?

Which has more volatility and risk, ATNM or PMN?

Does the media favor ATNM or PMN?

Do analysts rate ATNM or PMN?

Summary

How does Actinium Pharmaceuticals compare to Cibus?

Does the media favor CBUS or ATNM?

Which has stronger earnings & valuation, CBUS or ATNM?

Do institutionals & insiders have more ownership in CBUS or ATNM?

Do analysts prefer CBUS or ATNM?

Is CBUS or ATNM more profitable?

Which has more volatility and risk, CBUS or ATNM?

Summary

How does Actinium Pharmaceuticals compare to Inovio Pharmaceuticals?

Does the media prefer ATNM or INO?

Do analysts prefer ATNM or INO?

Do institutionals & insiders hold more shares of ATNM or INO?

Which has more volatility and risk, ATNM or INO?

Is ATNM or INO more profitable?

Which has preferable earnings & valuation, ATNM or INO?

Summary

How does Actinium Pharmaceuticals compare to Black Diamond Therapeutics?

Do institutionals & insiders have more ownership in BDTX or ATNM?

Which has more risk and volatility, BDTX or ATNM?

Does the media favor BDTX or ATNM?

Is BDTX or ATNM more profitable?

Which has better earnings and valuation, BDTX or ATNM?

Do analysts rate BDTX or ATNM?

Summary

How does Actinium Pharmaceuticals compare to ADC Therapeutics?

Which has stronger valuation and earnings, ATNM or ADCT?

Do analysts recommend ATNM or ADCT?

Does the media refer more to ATNM or ADCT?

Which has more volatility and risk, ATNM or ADCT?

Is ATNM or ADCT more profitable?

Do institutionals and insiders hold more shares of ATNM or ADCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools